Moderna Inc (MRNA)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
Volatility-scaled: the stop sits about 2× the average daily range (ATR 8.6% of price) below the price, with a 2:1 reward-to-risk target. Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+766% over the past year+10
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityRevenue growing 13% y/y-4
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product-related, driven by positive clinical/publication data for mNEXSPIKE and optimism around Moderna's personalized cancer vaccine pipeline. Continuation likelihood over the next few weeks is moderate (roughly 40–50%), as pipeline enthusiasm can fade without hard revenue or trial milestones to sustain momentum. Informational only — not financial advice.
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and OlderYahoo · 2026-11-11
- Moderna Stock Jumped 10% in 5 Sessions: Take Profits, or Buy More?Yahoo · 2026-11-11
- US Stock Market Today: S&P 500 Futures Rebound On Stubborn Inflation Higher-For-Longer RiskYahoo · 2026-11-11
- 10 Stocks Rode Trump Era — What Happens As MAGA 'Disintegrates'?Yahoo · 2026-11-11
- Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccineYahoo · 2026-11-11
Any AI summary is an interpretation of public news, not advice or a price target.